A single thioflavin-T (ThT) percentage or an "up to X%" cell-free value is a screening snapshot, not proof that a peptide or small molecule controls fibril formation. Abstracts published 1 June–1 September 2026 on amyloid-beta (Aβ), tau, transthyretin (TTR), and α-synuclein keep that number separate from a second physical readout and from cellular endpoints. This checklist, scoped to literature captured on 2 October 2026, is not a field review and does not treat any test article as an approved medicine.
What one aggregation curve can and cannot show
Karuturi et al. screened (1,4-diazepan-1-yl)(phenyl)methanone derivatives in a fluorescence-based ThT kinetic assay against Aβ42 and Aβ40. At 25 µM, compound 4m inhibited Aβ42 aggregation by 42.0%; 4k inhibited Aβ42 by 40.4% and Aβ40 by 57.3%; 4l inhibited Aβ42 by 36.1% and Aβ40 by 59.2%. Those figures are concentration-specific and isoform-specific. The abstract does not report a fitted IC50, which oligomeric species is populated, or the TEM morphology outcome.
Bagda et al. reported that the poly-arginine peptide R18D inhibited Aβ aggregation by up to 65% in a cell-free assay. "Up to" is a range, not a dose–response. The abstract does not name the detection chemistry, so that number cannot be pooled with a ThT percentage from another paper.
Sun et al. state the timing problem directly for TTR: species populations change over time and include a low-abundance monomeric intermediate, which is why quantifying which species an inhibitor binds has been difficult. A single end-point, or one incomplete curve, cannot assign the bound species.
None of these abstracts presents a bell-shaped dose–response as an artifact flag, and none reports that a test article itself formed colloidal aggregates. The practical limit is narrower: do not upgrade a single-concentration ThT or cytotoxicity percentage to a mechanism.
Orthogonal readouts used in these studies
The same abstracts pair the primary aggregation number with at least one independent method. That pairing is the evidence, not the first percentage alone.
| Primary readout | Follow-up in the abstract | What the pair can support |
|---|---|---|
| ThT kinetics (Aβ42/Aβ40) | TEM of fibril morphology; Aβ42 cytotoxicity in mouse hippocampal HT22 cells | Dye inhibition plus a morphology method; cytotoxicity is a separate cellular endpoint (Karuturi et al.) |
| Cell-free Aβ aggregation (chemistry unnamed) | MC65 cytotoxicity; HTRF of intracellular tau in SH-SY5Y cells and rat primary cortical neurons | Separate Aβ and tau endpoints in different models (Bagda et al.) |
| 19F-NMR TTR aggregation | Species-resolved affinities for tetramer versus monomeric intermediate | Which oligomeric state is bound under acidic, aggregating conditions (Sun et al.) |
| Membrane displacement of α-synuclein (FCS and fluorescence anisotropy) | ThT and TEM under membrane-inducing conditions; MTT, Seahorse, confocal uptake | Dose-dependent membrane binding versus fibril morphology versus cell function (Stefaniak et al.) |
After ThT, Karuturi et al. examined Aβ fibril morphology by transmission electron microscopy (TEM); the abstract does not report that TEM result. Compounds 4k-m significantly reduced Aβ42-induced cytotoxicity in HT22 cells. Compound 4l also showed antioxidant activity in a DPPH assay and attenuated hydrogen peroxide-induced cytotoxicity; PAMPA-BBB was used for permeability. Docking suggested contacts at both the N- and C-termini of Aβ42 and Aβ40. Antioxidant, permeability, and docking results do not measure aggregation.
Bagda et al. quantified intracellular tau by homogeneous time-resolved fluorescence 48 h after applying preformed tau seeds. R18D reduced aggregation by 34.8% in SH-SY5Y cells and 49.9% in rat primary cortical neurons; in human MC65 cells induced to overexpress APP-C99 and accumulate Aβ, it inhibited cellular toxicity by as much as 100%. Those percentages come from different models and endpoints. They are not one dose–response replicated three times.
Stefaniak et al. showed that SS-31 displaces wild-type and N-terminal acetylated α-synuclein from negatively charged small unilamellar vesicles in a dose-dependent manner (fluorescence correlation spectroscopy and fluorescence anisotropy), inhibits membrane-induced aggregation (ThT), and alters fibril morphology (TEM). Dose dependence here is membrane displacement, not an IC50 for fibril mass. MTT and Seahorse Mito Stress Test readouts in α-synuclein oligomer-treated neuroblastoma cells, and confocal imaging of oligomer uptake, are cellular observations—not substitutes for the biophysical pair.
Concentration-dependent numbers that are easy to over-read
Several concentration facts in these abstracts are easy to promote to potency:
- Dual Aβ42/Aβ40 inhibition was reported at a single 25 µM test concentration, not as a full curve (Karuturi et al.).
- R18D Aβ inhibition is an upper bound ("up to 65%"), and the tau reductions are model-specific percentages after 48 h (Bagda et al.).
- For TTR, using diflunisal as a model compound, tetramer binding became approximately 2-fold tighter and monomer binding 15-fold stronger at acidic pH versus neutral pH. Concatenating two capping peptides increased affinity to tetramers and monomeric intermediates by about 2-fold relative to the same peptides mixed separately at equal concentrations (Sun et al.). A pH or valency change of that size would look like a different hit if the screen were run at one condition.
- SS-31 membrane displacement is explicitly dose-dependent; ThT and TEM then address aggregation and morphology under membrane-inducing conditions (Stefaniak et al.).
Do not treat pH-, membrane-, or species-dependent affinity shifts as noise, and do not average them with a single-point ThT rank.
Checklist before calling a peptide an aggregation hit
- Record the amyloid species (Aβ40 versus Aβ42; TTR tetramer versus monomer; membrane-bound versus free α-synuclein) and the exact test concentration and time.
- Keep dye or cell-free inhibition separate from morphology (TEM) or species-resolved spectroscopy (19F-NMR).
- Do not average cell-free aggregation, cytotoxicity, and intracellular HTRF into one activity score.
- Treat "up to X%" and single-concentration percent inhibition as screening ranks, not IC50 values.
- If assay pH, membrane composition, or peptide valency can shift affinity several-fold, match those conditions in any follow-up.
- Score antioxidant, permeability, mitochondrial, or docking results as distinct endpoints, not as aggregation confirmation.
One question these abstracts leave open is how a single-concentration ThT rank (for example 25 µM versus Aβ42) should be compared with a species-resolved NMR affinity measured while oligomer populations are still changing. Until that mapping is shown, the decision rule grounded in these studies is to require at least two orthogonal physical readouts before an incomplete dose–response is called aggregation evidence.
Frequently Asked Questions
Does ThT inhibition alone establish that fibrils were reduced?
No. Stefaniak et al. reported ThT inhibition of membrane-induced α-synuclein aggregation and, separately, altered fibril morphology by TEM. Karuturi et al. followed ThT with TEM of Aβ fibril morphology, but that abstract does not report the TEM outcome. The dye kinetic result is not a morphology result.
Can R18D’s “up to 65%” Aβ inhibition be ranked against 42.0% inhibition by compound 4m at 25 µM?
Not from these abstracts. Bagda et al. report an upper bound in an unnamed cell-free Aβ assay; Karuturi et al. report a single-concentration ThT value against Aβ42. Different detection methods, reporting formats, and concentrations are not interchangeable ranks.
Should HT22 or MC65 cytotoxicity be counted as aggregation confirmation?
No. Karuturi et al. assessed attenuation of Aβ42-induced cytotoxicity in mouse hippocampal HT22 cells after the ThT screen. Bagda et al. reported inhibition of MC65 cellular toxicity separately from the cell-free Aβ assay. Those are cellular endpoints, not fibril-mass measurements.
Explore Further
Browse our research peptide catalog and review third-party lab reports & COAs for published batches.
---
Research use only. The information above is provided for educational and laboratory research purposes only. The compounds discussed are not approved for human or veterinary use, diagnosis, treatment, or the prevention of any disease. Nothing here is medical advice.